Asylia News

Asylia Therapeutics News

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy.  Houston, May 25, 2021 – Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 …

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing Read More »

Asylia Therapeutics News

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System

Houston: the true third coast of innovation. Texas is home to more than 5,400 life science R&D and manufacturing firms, with more than 106,000 workers employed in related fields (THBI). As one of the top global biotechnology hubs, and home to the largest medical center in the world (Texas Medical Center), it’s no wonder JLABS …

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System Read More »

Asylia Therapeutics News

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement

Asylia Therapeutics (“Asylia”), a new, privately-held, development stage biopharmaceutical company, headquartered in Houston at the Texas Medical Center, has finalized an exclusive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop first-in-class immune modulating therapies for cancer, autoimmune and infectious diseases, which collectively impact tens of millions of Americans annually. …

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement Read More »

Asylia Therapeutics News

Asylia Therapeutics Moves into JLABS @TMC

Houston, Texas. June 6, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases has officially landed at Johnson & Johnson Innovation – JLABS in the Texas Medical Center (JLABS @ TMC). With over 34,000 square feet of common, wet lab, and office …

Asylia Therapeutics Moves into JLABS @TMC Read More »

Asylia Therapeutics News

CPRIT Awards $3 Million to Asylia Therapeutics

Houston, Texas.  May 11, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases, today announced it has received a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT). Asylia will use the funding …

CPRIT Awards $3 Million to Asylia Therapeutics Read More »

Scroll to Top